Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On August 13, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for…

Unregistered Sales of Equity Securities. The disclosures in

Entry into a Material Definitive Agreement. Private Placement Offering On August 4, 2026, Grace Therapeutics, Inc. (the “Company”), in connection with a private placement offering (the “Offering”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), entered into with certain institutional and accredited investors (the “Investors”) (i) a securities purchase agreement (the “Purchase Agreement”), and (ii) a registration rights agreement (the “Registration Rights Agreement”). Pu…

Other Events. On July 28, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing receipt of the U.S. Food and Drug Administration (“FDA”) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter issued on April 23, 2026 for the Company’s GTx-104 new drug application. In addition, the Company updated its corporate presentation on July 28, 2026 to reflect the path to NDA resubmission following the Type A Meeting. A copy of the pre…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On June 18, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for p…

Vice President of Clinical Operations — Carrie D’Andrea: Carrie D'Andrea ceased serving as Vice President of Clinical Operations and will no longer be employed by the Company.

Other Events On April 23, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s New Drug Application for GTx-104 in the treatment of patients with aneurysmal subarachnoid hemorrhage. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On February 12, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “file…

The company amended severance terms for several executive officers.

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On November 13, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “fil…

Other Events. On October 23, 2025, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company has secured approximately $4.0 million in additional funding through exercises of common warrants that were previously issued in a private placement that the Company closed in September 2023. The remaining 1,190,927 common warrants issued in the 2023 private placement have expired as the 60th day after the U.S. Food and Drug Administration’s acceptance for review of t…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 12, 2025, Grace Therapeutics, Inc. issued a press release announcing its financial results for the three months ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Sec…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.” On June 23, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 13, 2025, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not…

Unregistered Sales of Equity Securities. The disclosures in

Entry into a Material Definitive Agreement. Private Placement Offering On February 10, 2025, Grace Therapeutics, Inc. (the “Company”), in connection with a private placement offering of the Company’s securities (the “Offering”), entered into with certain institutional and accredited investors (the “Investors”) (i) a securities purchase agreement involving a placement agent (the “Placement Agent Purchase Agreement”), (ii) a securities purchase agreement not involving a placement agent (the “No…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On November 13, 2024, Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall no…

Material Modification to Rights of Security Holders. In connection with the consummation of the Continuance, the Company adopted a continuation application, which contained the Notice of Articles of Acasti British Columbia (the “Notice of Articles”) and the Articles of Acasti British Columbia (the “Articles”), each of which is described in the Company’s Proxy Statement/Prospectus, which was filed with the Securities and Exchange Commission on August 7, 2024 and is a part of the Company’s regi…

Entry into a Material Definitive Agreement. On October 7, 2024, in connection with the consummation of the Domestication and pursuant to the Company’s Charter (as defined below), Bylaws (as defined below) and the DGCL, the Company entered into indemnification agreements with each of the Company’s executive officers and directors providing for the indemnification of, and advancement of expenses to, each such person in connection with claims, suits or proceedings arising as a result of such per…

The excerpt is incomplete and does not provide specific details about the movement or event.

Chief Executive Officer — Prashant Kohli: Mr. Kohli entered into a new employment agreement with the company, outlining his compensation and benefits.

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On August 9, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On June 21, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal year ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18…

Results of Operations and Financial Condition. The following information is furnished pursuant to Item 2.02 "Results of Operations and Financial Condition." On February 12, 2024, Acasti Pharma Inc. issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of S…

principal financial officer and principal accounting officer — Robert J. DelAversano: Robert J. DelAversano was promoted to principal financial officer and principal accounting officer.